ID   HL-60/DNR
AC   CVCL_4458
SY   HL60/DNR; HL60-DNR
DR   BTO; BTO:0003573
DR   cancercelllines; CVCL_4458
DR   Wikidata; Q54889804
RX   PubMed=9557624;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 23
//
RX   PubMed=9557624; DOI=10.1038/sj.leu.2400976;
RA   Mattii L., Barale R., Petrini M.;
RT   "Use of the comet test in the evaluation of multidrug resistance of
RT   human cell lines.";
RL   Leukemia 12:627-632(1998).
//